Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer

NCT01256567 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01256567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01256567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
February 28, 2013
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic breast cancer